Clinical Trial Update: Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating lenalidomide, bortezomib, and dexamethasone with CNTO 328 (siltuximab) in transplant-eligible newly diagnosed multiple myeloma; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Decadron (Dexamethasone)
• Revlimid (lenalidomide)
• Siltuximab (siltuximab)
• Velcade (bortezomib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-06-19